About Safe TB-500

What this site is

Safe TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "safe" in our name is an editorial posture, not a claim about the compound or about any service we offer. It signals a research-safety register — a commitment to reporting what the evidence genuinely establishes, to marking the human-data gaps as gaps rather than papering over them, and to never dressing an uncharacterized fragment in the reassurance language of a finished, approved medicine. It is a way of reading the literature, not a verdict that TB-500 is safe.

Why the fragment-versus-parent distinction drives everything

Most TB-500 coverage quietly cites full-length thymosin beta-4 studies as if they were TB-500 studies. They are not the same molecule: TB-500 is the ~889-dalton Ac-LKKTETQ fragment, and the parent protein is a ~4963-dalton chain whose efficacy record dwarfs the fragment's ^[1]. We built this digest specifically to keep that line visible on every page — to label which molecule each number belongs to, and to state plainly that no completed controlled human trial has tested the heptapeptide for any indication ^[4].

That editorial discipline is the whole value proposition. A solved actin-binding structure is reported as a solved structure ^[1]; a reproduced rat wound figure is reported as an animal figure ^[2]; a tumor/angiogenesis signal is reported as a signal, not a risk demonstrated for the fragment ^[12]; and a regulatory status is reported with its FDA citation rather than as folklore ^[16].

How we cite

Every quantitative claim on this site — every dose, percentage, duration, and effect size — maps to a numbered entry on the references page, drawn from peer-reviewed journals, a randomized Phase 1 trial, a ClinicalTrials.gov registration, and FDA pages. We do not publish a claim that is not in the cited record. When the honest answer to a question is that no human data exist, that is the answer we give.

What the name modifier means

The word "Safe" in "Safe TB-500" is editorial framing — a position this publisher occupies relative to the literature, a careful and skeptical reading — not a statement that the compound is safe and not a claim that this site offers treatment, consultation, or any product. We hold no clinical relationship with any reader. For the regulatory facts that bear on access, see the legal-status page, which is sourced entirely to FDA.